Key diabetes drug to cost up to 90% less in a few days
Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, following the expiry of its patent. Estimated to significantly cut costs and improve access for over 10 crore diabetics, Mankind Pharma and others will offer the drug at a fraction of its original cost, easing financial burdens and enhancing heart and kidney health.
Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, following the expiry of its patent. Estimated to significantly cut costs and improve access for over 10 crore diabetics, Mankind Pharma and others will offer the drug at a fraction of its original cost, easing financial burdens and enhancing heart and kidney health.
